- Market Value (2025): USD 160.8 Mn
- Estimated Value (2026): USD 170.8 Mn
- Forecast Value (2036): USD 311.9 Mn
- CAGR (2026-2036): 6.2%
Gastrodin Market Forecast and Outlook 2026 to 2036
Global gastrodin sales were valued at USD 160.8 million in 2025 and USD 170.8 million in 2026. The market is projected to reach USD 311.9 million by 2036, reflecting a 6.2% CAGR over 2026–2036.
Powder accounts for 38.2% of the gastrodin market in 2026, while pharmaceutical applications hold 41.3%. Online stores contribute 29.4%, and hospitals lead end-user purchases at 35.4%. Extracted from Gastrodia elata, gastrodin is attracting pharmaceutical research interest because of its potential neuroprotective and anti-inflammatory properties. Ongoing neurological studies are creating opportunities for ingredient manufacturers, although clinical validation, consistent product quality and regulatory requirements continue to influence wider commercial use.
Key Takeaways from the Gastrodin Market
- Gastrodin Market Value (2025): USD 160.8 million
- Gastrodin Market Value (2026): USD 170.8 million
- Gastrodin Market Forecast Value (2036): USD 311.9 million
- Gastrodin Market Forecast CAGR (2026–2036): 6.2%
- Leading Product Type: Powder (38.2%)
- Leading Application: Pharmaceuticals (41.3%)
- Leading Distribution Channel: Online Stores (29.4%)
- Leading End User: Hospitals (35.4%)
- Key Market Participants: Chengdu Biopurify Phytochemicals Ltd., Xi'an Lyna Bio-Tech Co., Ltd., Xi'an Lyphar Biotech Co., Ltd., Shaanxi Huike Botanical Development Co., Ltd., Xi'an Natural Field Bio-Technique Co., Ltd., Shaanxi Undersun Biomedtech Co., Ltd., Hunan Nutramax Inc. and Xi'an Herbking Biotechnology Co., Ltd.
- Key Growth Regions: Germany, Brazil, United States, United Kingdom and Japan
Pharmaceutical companies and healthcare institutions account for a significant part of gastrodin-related activity because researchers are examining its potential in neurological treatments. Powder leads the product segment with 38.2% in 2026, while pharmaceutical applications hold 41.3%. In May 2025, Frontiers in Pharmacology published a review on gastrodin’s potential to prevent and treat cerebral ischemia-reperfusion injury.
Gastrodin Market
| Metric | Value |
|---|---|
| Estimated Value in (2025) | USD 160.8 million |
| Estimated Value in (2026) | USD 170.8 million |
| Forecast Value in (2036) | USD 311.9 million |
| Forecast CAGR (2026 to 2036) | 6.2% |
Source: Fact.MR analysis. Updated Nov 17, 2026
Source: Fact.MR analysis. Updated 14 Nov 2026

Gastrodin Market Forecast Global | Source: Fact.MR
Category
| Category | Segments |
|---|---|
| Product Type | Powder, Capsules, Tablets, Liquid |
| Application | Pharmaceuticals, Dietary Supplements, Cosmetics, Research and Development |
| Distribution Channel | Online Stores, Pharmacies, Health Stores, Others |
| End-User | Hospitals, Clinics, Individual Consumers, Research Institutes |
| Region | Germany, Brazil, United States, United Kingdom, Japan |
Source: Fact.MR analysis. Updated Nov 17, 2026
Segmental Analysis
Why does powder lead product type demand in the Gastrodin Market?

Gastrodin Market Breakdown Product Type | Source: Fact.MR
Powder leads the gastrodin product segment with a 38.2% share in 2026. In June 2025, researchers published a study on a gastrodin and ferulic acid liposomal gel patch for migraine treatment, illustrating the range of dosage forms being explored for the compound. Powder holds an advantage because manufacturers can measure, blend and process it into different formulations. Capsules and tablets suit buyers seeking fixed-dose formats, while liquid preparations offer flexibility for formulations where swallowing solid doses is difficult.
Why do pharmaceutical applications lead in the Gastrodin Market?

Gastrodin Market Breakdown Application | Source: Fact.MR
A February 2025 study published in Acta Pharmacologica Sinica examined how gastrodin supports central nervous system myelin formation and reduces demyelinating injury. Pharmaceuticals lead the application segment with 41.3% in 2026 because research into neurological conditions gives gastrodin a clear therapeutic focus. Dietary supplements appeal to consumers seeking botanical ingredients, while cosmetics use it in specialised formulations. Research and development purchases also continue as laboratories investigate its mechanisms and possible applications.
Why do online stores lead distribution channels in the Gastrodin Market?

Gastrodin Market Breakdown Distribution Channel | Source: Fact.MR
In October 2026, The Ingredients Store partnered with Vantage to list specialty ingredients and botanical extracts on its digital platform, giving formulators access to technical details and flexible order quantities. Online stores lead gastrodin distribution with 29.4% in 2026 because digital catalogues help pharmaceutical buyers compare purity, specifications and prices across suppliers. B2B platforms serve bulk ingredient purchases, while consumer-focused websites cater to smaller supplement orders. Pharmacies handle healthcare-related purchases, whereas health stores mainly serve buyers seeking botanical and wellness products.
Why do hospitals lead end-user demand in the Gastrodin Market?

Gastrodin Market Breakdown End User | Source: Fact.MR
A March 2025 clinical trial conducted at Union Hospital in Wuhan examined gastrodin infusion for preventing delirium in patients recovering from cardiac surgery. The study reported a lower incidence of postoperative delirium in the gastrodin group than in the placebo group. Hospitals lead the end-user segment with 35.4% in 2026 because they handle specialised neurological care and clinical investigations. Clinics serve patients through specialised services, while research institutes purchase gastrodin for laboratory studies. Individual consumers access it through permitted supplement and wellness products.
Gastrodin Market-Drivers, Restraints & Trends
Drivers: Rising Pharmaceutical Research into Neuroprotective Compounds:
A February 2026 review in the American Journal of Chinese Medicine examined gastrodin and gastrodigenin as potential neuroprotective compounds for neurodegenerative diseases. This research interest is increasing because pharmaceutical developers are exploring naturally derived ingredients with antioxidant, anti-inflammatory and neuroprotective properties for neurological applications. Further investigation into these compounds is creating opportunities for gastrodin manufacturers to serve pharmaceutical research organisations and drug developers seeking consistent purity, quality testing and reliable ingredient documentation.
- Restraints: Despite research interest in gastrodin, its commercial use faces hurdles because promising laboratory findings do not establish clinical effectiveness or guarantee regulatory acceptance. Manufacturers must verify ingredient purity, safety and batch consistency while meeting country-specific quality and labelling standards. In the United States, the FDA does not approve dietary supplements for safety and effectiveness before they enter the market. These compliance obligations can increase testing expenses and make it more difficult for gastrodin manufacturers to enter international markets.
- Trend: Expanding Research into Neurological Applications: A May 2025 review in Frontiers in Pharmacology examined gastrodin's pharmacological mechanisms in cerebral ischemia-reperfusion injury, including its antioxidant and anti-inflammatory activity. Such investigations are serving attention to gastrodin as a potential ingredient for neurological drug research. Pharmaceutical developers are discovering its accuracy across various neurological pathways, while ingredient manufacturers are concentratin on research-grade purity, analytical testing and formulation suitability.
- Trend: Greater Focus on Botanical Ingredient Standardisation: Variations in extraction methods and raw material composition can affect gastrodin concentration and batch quality, making consistency an important purchasing consideration. Pharmaceutical companies and research laboratories increasingly assess ingredient identity, impurity levels and analytical records before selecting botanical compounds. This is encouraging manufacturers to strengthen extraction controls, chromatographic testing and batch traceability to meet the quality expectations of specialised research and pharmaceutical customers.
Gastrodin Market by Analysis by Key Country

Gastrodin Market Growth Index | Source: Fact.MR
| Country | CAGR (2026–2036) |
|---|---|
| Germany | 6.8% |
| Brazil | 5.5% |
| United States | 7.8% |
| United Kingdom | 7.4% |
| Japan | 5.2% |
Source: Fact.MR analysis. Updated Nov 17, 2026
Source: Fact.MR analysis. Updated 14 Nov 2026
What is driving gastrodin market growth in Germany?
Germany's pharmaceutical industry generated EUR 67.9 billion in revenue in 2025, supported by more than 650 pharmaceutical companies, according to Germany Trade & Invest.
This extensive manufacturing base creates opportunities for specialised ingredients such as gastrodin, particularly in neurological drug research and formulation studies. Sales are driven by pharmaceutical R&D, interest in standardised botanical compounds and the need for research-grade ingredients with documented purity. Germany's market is projected to expand at a CAGR of 6.8% from 2026 to 2036.
What is supporting gastrodin market growth in Brazil?
Interest in specialised pharmaceutical ingredients is creating opportunities for gastrodin suppliers as Brazil expands its domestic medicine industry. In September 2026, ANVISA reported that the Brazilian pharmaceutical market generated approximately BRL 182 billion in revenue in 2025, registering nominal growth of 13.7%.
The expanding industry creates room for botanical compounds used in pharmaceutical investigation and formulation research. Sales are driven by specialised ingredient sourcing, neurological research and demand for consistent ingredient quality. Brazil is projected to record a 5.5% CAGR through 2036.
What is driving gastrodin market growth in the United States?
The United States offers a strong research environment for gastrodin because pharmaceutical developers and biomedical institutions investigate compounds with potential neurological applications. The National Institutes of Health reported USD 35.3 billion in extramural research grant investments for FY 2025 in March 2026.
This research ecosystem creates opportunities for specialised ingredients used in laboratory investigations and formulation studies. Sales are influenced by interest in neuroprotective compounds, research-grade purity and reliable analytical documentation. The US market is projected to grow at a 7.8% CAGR between 2026 and 2036.
What is supporting gastrodin market growth in the United Kingdom?
The UK's pharmaceutical export network creates commercial opportunities for specialised ingredient manufacturers, including those serving gastrodin-related research. According to the Association of the British Pharmaceutical Industry, the country exported £38.7 billion worth of medicinal and pharmaceutical products in 2025.
Its international manufacturing connections and life sciences research capabilities create avenues for botanical ingredient evaluation. Sales are driven by neurological research, pharmaceutical formulation studies and preference for ingredients with traceable quality records. The UK market is projected to register a 7.4% CAGR from 2026 to 2036.
What is sustaining gastrodin market growth in Japan?
Japan's ageing population and pharmaceutical research activities create opportunities for specialised compounds investigated for neurological applications. The US Commercial Service's November 2025 pharmaceutical industry report estimated Japan's pharmaceutical market at USD 87.37 billion for 2025.
This substantial pharmaceutical base offers opportunities for gastrodin manufacturers targeting research and formulation applications. Sales are influenced by interest in specialised botanical ingredients, consistent purity, formulation compatibility and documented manufacturing quality. Japan's market is projected to expand at a 5.2% CAGR between 2026 and 2036.
Competitive Landscape for Gastrodin Market
The gastrodin market includes several botanical ingredient manufacturers, with competition extending beyond product availability to the quality and consistency of specialised extracts. Companies active in this landscape include Chengdu Biopurify Phytochemicals Ltd., Xi'an Lyna Bio-Tech Co., Ltd., Xi'an Lyphar Biotech Co., Ltd., Shaanxi Huike Botanical Development Co., Ltd., Xi'an Natural Field Bio-Technique Co., Ltd., Shaanxi Undersun Biomedtech Co., Ltd., Hunan Nutramax Inc. and Xi'an Herbking Biotechnology Co., Ltd.
Their wider phytochemical and plant extract portfolios place them in the relevant ingredient supply chain. For gastrodin buyers, the deciding factors include verified purity, extraction quality, batch uniformity, testing records and order flexibility. Manufacturers that maintain dependable specifications and meet international quality requirements can strengthen relationships with pharmaceutical developers, supplement producers and research laboratories.
Recent Developments
- On November 11, 2025, Chengdu Biopurify Phytochemicals Ltd. participated in the AAES 2025 Natural Health Products Exhibition, showcasing botanical extracts and research-related products.
- On October 30, 2025, Xi'an Lyna Bio-Tech Co., Ltd. published an update on cornflower flower extract and its applications in skincare and cosmetic formulations.
- On September 4, 2026, Xi'an Natural Field Bio-Technique Co., Ltd. introduced its NFTriSolve® plant-derived co-loaded liposome health solutions.
- On June 10, 2026, Hunan Nutramax Inc. announced its participation in CPHI China 2026, showcasing natural sweeteners and botanical extracts.
- On May 21, 2025, Shaanxi Undersun Biomedtech Co., Ltd. participated in Vitafoods Europe 2025 in Barcelona, presenting mushroom powders and extracts for dietary supplements and functional foods.
Key Players in Gastrodin Market
Key companies profiled include Chengdu Biopurify Phytochemicals Ltd.; Xi'an Lyna Bio-Tech Co., Ltd.; Xi'an Lyphar Biotech Co., Ltd.; Shaanxi Huike Botanical Development Co., Ltd.; Xi'an Natural Field Bio-Technique Co., Ltd.; Shaanxi Undersun Biomedtech Co., Ltd.; Hunan Nutramax Inc.; and Xi'an Herbking Biotechnology Co., Ltd.
- Chengdu Biopurify Phytochemicals Ltd.
- Xi'an Lyna Bio-Tech Co., Ltd.
- Xi'an Lyphar Biotech Co., Ltd.
- Shaanxi Huike Botanical Development Co., Ltd.
- Xi'an Natural Field Bio-Technique Co., Ltd.
- Shaanxi Undersun Biomedtech Co., Ltd.
- Hunan Nutramax Inc.
- Xi'an Herbking Biotechnology Co., Ltd.
Bibliography
- Agência Nacional de Vigilância Sanitária. (2026, September 28). CMED divulga 9° edição do Anuário Estatístico do Mercado Farmacêutico.
- Association of the British Pharmaceutical Industry. (n.d.). Facts, figures and industry data.
- Bai, Y.-X., Wu, H.-L., Xie, W.-L., Li, X., Han, J.-J., Liu, J., Chen, S.-Q., Yin, P., Dong, N.-G., & Wu, Q.-P. (2025). Efficacy and safety of gastrodin in preventing postoperative delirium following cardiac surgery: A randomized placebo controlled clinical trial. Critical Care, 29, Article 108.
- Germany Trade & Invest. (n.d.). Pharmaceutical industry.
- Holmes, C. (2026, October 9). Vantage agrees new partnership with The Ingredients Store® to expand digital access to specialty ingredients. The Ingredients Store.
- Qin, W., Du, J., Wang, F., & Xu, J. (2025). Gastrodin: A potential natural product for the prevention and treatment of cerebral ischemia-reperfusion injury. Frontiers in Pharmacology, 16, Article 1554170.
- Shi, X.-Y., He, Y.-X., Ge, M.-Y., Liu, P., Zheng, P., & Li, Z.-H. (2025). Gastrodin promotes CNS myelinogenesis and alleviates demyelinating injury by activating the PI3K/AKT/mTOR signaling. Acta Pharmacologica Sinica, 46, 1610–1623.
- The Ingredients Store. (2026, October 9). Vantage agrees new partnership with The Ingredients Store® to expand digital access to specialty ingredients.
- U.S. Food and Drug Administration. (n.d.). Information for consumers on using dietary supplements.
- U.S. International Trade Administration. (2025, November 20). Japan: Pharmaceuticals.
- U.S. National Institutes of Health. (2026, March 12). Fiscal year 2025 by the numbers: Extramural grant investments in research.
- Wang, J., Chen, T., Lin, Y., Shen, X., & Zhou, M. (2026). Gastrodin and gastrodigenin as potential neuroprotectors for the treatment of neurodegenerative diseases. The American Journal of Chinese Medicine, 54(2), 529–554.
- Wang, J., Gu, X., Gao, X., Gao, H., Chen, J., Lv, Z., Chen, L., Xu, Y., Chen, X., Cao, L., Wang, Z., Tian, J., & Xiao, W. (2025). Preparation and evaluation of gastrodin-ferulic acid co-loaded liposome gel patches for the treatment of migraine. Drug Development and Industrial Pharmacy.
- Zhang, B., Zhu, H., Zhang, L., Luo, M.-C., Li, X., & Liu, D. (2025). Evaluation of quality characteristics of 15 Gastrodia elata germplasm resources based on HS-SPME-GC-MS, HPLC and electronic nose techniques. Food Bioscience, 71, Article 107158.
Segmentation
Scope of Report

Gastrodin Market Taxonomy | Source: Fact.MR
| Items | Values |
|---|---|
| Quantitative Units (2026) | USD 170.8 Million |
| Product Type | Powder, Capsules, Tablets, Liquid |
| Application | Pharmaceuticals, Dietary Supplements, Cosmetics, Research and Development |
| Distribution Channel | Online Stores, Pharmacies, Health Stores, Others |
| End-User | Hospitals, Clinics, Individual Consumers, Research Institutes |
| Regions Covered | North America, Latin America, Europe, Asia Pacific, Middle East & Africa |
| Countries Covered | Germany, Brazil, United States, United Kingdom, Japan, and other countries |
| Key Companies Profiled | Chengdu Biopurify Phytochemicals Ltd., Xi'an Lyna Bio-Tech Co., Ltd., Xi'an Lyphar Biotech Co., Ltd., Shaanxi Huike Botanical Development Co., Ltd., Xi'an Natural Field Bio-Technique Co., Ltd., Shaanxi Undersun Biomedtech Co., Ltd., Hunan Nutramax Inc., Xi'an Herbking Biotechnology Co., Ltd. |
| Additional Attributes | Dollar revenue in the Gastrodin Market is segmented by product type, application, distribution channel, end-user and region. |
Source: Fact.MR analysis. Updated Nov 17, 2026
Gastrodin Market by Segments
-
Product Type
- Powder
- Capsules
- Tablets
- Liquid
-
Application
- Pharmaceuticals
- Dietary Supplements
- Cosmetics
- Research and Development
-
Distribution Channel
- Online Stores
- Pharmacies
- Health Stores
- Others
-
End-User
- Hospitals
- Clinics
- Individual Consumers
- Research Institutes
-
Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
- North America
Frequently Asked Questions
How big is the global Gastrodin Market in 2026?
What will be the size of the Gastrodin Market by 2036?
How fast will the Gastrodin Market grow during the forecast period?
Which product type segment holds the largest share of the Gastrodin Market?
Which application segment leads the Gastrodin Market?
Which distribution channel leads the Gastrodin Market?
Who are the key companies operating in the Gastrodin Market?
Who worked on this report
Preview the report firsthand - request a free sample
Free SampleGet the brochure for pricing and purchase details
Download PDF